Book contents
- Alzheimer’s Disease Drug Development
- Alzheimer’s Disease Drug Development
- Copyright page
- Dedication
- Contents
- Contributors
- Foreword
- Acknowledgments
- Section 1 Advancing Alzheimer’s Disease Therapies in a Collaborative Science Ecosystem
- Section 2 Non-clinical Assessment of Alzheimer’s Disease Candidate Drugs
- Section 3 Alzheimer’s Disease Clinical Trials
- 11 Phase 1 Trials in Alzheimer’s Disease Drug Development
- 12 The Importance of Phase 2 in Drug Development for Alzheimer’s Disease
- 13 Alzheimer’s Disease Drug Development in Pharmaceutical Companies
- 14 Trial Site Infrastructure and Management: Importance to Alzheimer’s Disease Drug Development
- 15 ATRI and ACTC: Academic Programs to Accelerate Alzheimer’s Disease Drug Development
- 16 The European Prevention of Alzheimer’s Disease Program: A Public–Private Partnership to Facilitate the Secondary Prevention of Alzheimer’s Disease Dementia
- 17 The Global Alzheimer’s Platform Foundation®: Delivering New Medicines Faster by Accelerating Clinical Trials
- 18 Clinical Trial Development in Frontotemporal Lobar Degeneration
- 19 Statistical Considerations in the Design and Analysis of Alzheimer’s Disease Clinical Trials
- 20 Alzheimer’s Disease Trial Recruitment and Diversifying Trial Populations
- 21 The Role of Online Registries in Accelerating Alzheimer’s Disease Drug Development
- 22 Data Safety Monitoring Boards in Alzheimer’s Disease Trials
- 23 Globalization of Alzheimer’s Disease Clinical Trials
- 24 The Use and Development of Clinical Measures of Alzheimer’s Disease Trials
- 25 Tele-Trials, Remote Monitoring, and Trial Technology for Alzheimer’s Disease Clinical Trials
- 26 Expanded Access and Compassionate Use in Alzheimer’s Disease Drug Development
- 27 The Role of the Contract Research Organization in Alzheimer’s Disease: The Vital Link in the Clinical Drug-Development Program
- 28 The Role of Regulatory Agencies in Alzheimer’s Disease Drug Development
- 29 Alzheimer’s Disease Clinical Trial Study Partners
- 30 From Trials to Practice: Are We Ready for a Disease-Modifying Treatment?
- 31 Best Practices for Clinical Trials during COVID-19
- Section 4 Imaging and Biomarker Development in Alzheimer’s Disease Drug Discovery
- Section 5 Academic Drug-Development Programs
- Section 6 Public–Private Partnerships in Alzheimer’s Disease Drug Development
- Section 7 Funding and Financing Alzheimer’s Disease Drug Development
- Index
- References
16 - The European Prevention of Alzheimer’s Disease Program: A Public–Private Partnership to Facilitate the Secondary Prevention of Alzheimer’s Disease Dementia
from Section 3 - Alzheimer’s Disease Clinical Trials
Published online by Cambridge University Press: 03 March 2022
Book contents
- Alzheimer’s Disease Drug Development
- Alzheimer’s Disease Drug Development
- Copyright page
- Dedication
- Contents
- Contributors
- Foreword
- Acknowledgments
- Section 1 Advancing Alzheimer’s Disease Therapies in a Collaborative Science Ecosystem
- Section 2 Non-clinical Assessment of Alzheimer’s Disease Candidate Drugs
- Section 3 Alzheimer’s Disease Clinical Trials
- 11 Phase 1 Trials in Alzheimer’s Disease Drug Development
- 12 The Importance of Phase 2 in Drug Development for Alzheimer’s Disease
- 13 Alzheimer’s Disease Drug Development in Pharmaceutical Companies
- 14 Trial Site Infrastructure and Management: Importance to Alzheimer’s Disease Drug Development
- 15 ATRI and ACTC: Academic Programs to Accelerate Alzheimer’s Disease Drug Development
- 16 The European Prevention of Alzheimer’s Disease Program: A Public–Private Partnership to Facilitate the Secondary Prevention of Alzheimer’s Disease Dementia
- 17 The Global Alzheimer’s Platform Foundation®: Delivering New Medicines Faster by Accelerating Clinical Trials
- 18 Clinical Trial Development in Frontotemporal Lobar Degeneration
- 19 Statistical Considerations in the Design and Analysis of Alzheimer’s Disease Clinical Trials
- 20 Alzheimer’s Disease Trial Recruitment and Diversifying Trial Populations
- 21 The Role of Online Registries in Accelerating Alzheimer’s Disease Drug Development
- 22 Data Safety Monitoring Boards in Alzheimer’s Disease Trials
- 23 Globalization of Alzheimer’s Disease Clinical Trials
- 24 The Use and Development of Clinical Measures of Alzheimer’s Disease Trials
- 25 Tele-Trials, Remote Monitoring, and Trial Technology for Alzheimer’s Disease Clinical Trials
- 26 Expanded Access and Compassionate Use in Alzheimer’s Disease Drug Development
- 27 The Role of the Contract Research Organization in Alzheimer’s Disease: The Vital Link in the Clinical Drug-Development Program
- 28 The Role of Regulatory Agencies in Alzheimer’s Disease Drug Development
- 29 Alzheimer’s Disease Clinical Trial Study Partners
- 30 From Trials to Practice: Are We Ready for a Disease-Modifying Treatment?
- 31 Best Practices for Clinical Trials during COVID-19
- Section 4 Imaging and Biomarker Development in Alzheimer’s Disease Drug Discovery
- Section 5 Academic Drug-Development Programs
- Section 6 Public–Private Partnerships in Alzheimer’s Disease Drug Development
- Section 7 Funding and Financing Alzheimer’s Disease Drug Development
- Index
- References
Summary
The ongoing European Prevention of Alzheimer’s Dementia Programme (EPAD) was established in 2015 to create a platform for Phase 2 testing of interventions for the secondary prevention of Alzheimer’s disease (AD) dementia. This initiative was the largest of its kind globally. The original funding from the Innovative Medicines Initiative ensured that through their public-private partnership model, the programme benefited from expertise, know-how, and resources from academia, the pharmaceutical arena and third sector. Setting the vision, managing the innovative programme and operationalising scores of crucial and interdependent elements was a substantial governance and project management undertaking. The programme is ongoing with data and samples accessible through state-of-the-art systems in partnership with the Alzheimer’s Disease Data Interoperability programme. Follow-up of research participants is being organised and their involvement in a range of clinical trials is being facilitated via collaboration with the Global Alzheimer’s Platform. The challenges and lessons learned from EPAD are important as the field continued to advance and new therapies are developed.
Keywords
- Type
- Chapter
- Information
- Alzheimer's Disease Drug DevelopmentResearch and Development Ecosystem, pp. 190 - 206Publisher: Cambridge University PressPrint publication year: 2022
References
Ritchie, CW, Molinuevo, JL, Satlin, A, et al. The European Prevention of Alzheimer’s Dementia (EPAD) Consortium: a platform to enable the secondary prevention of Alzheimer’s dementia through improved proof of concept trials. Lancet Psychiatry 2016; 3: 179–86.CrossRefGoogle Scholar
Gregory, S, Wells, K, Forsyth, K, et al. Research participants as collaborators: background, experience and policies from the PREVENT Dementia and EPAD programmes. Dementia 2018; 17: 1045–54.CrossRefGoogle ScholarPubMed
Ritchie, K, Ritchie, CW. The PREVENT study: a prospective cohort study to identify mid-life biomarkers of late-onset Alzheimer’s disease. BMJ Open 2012; 2: e001893.CrossRefGoogle ScholarPubMed
Vermunt, L, Veal, CD, Ter Meulen, L, et al. European Prevention of Alzheimer’s Dementia Registry: recruitment and prescreening approach for a longitudinal cohort and prevention trials. Alzheimers Dement 2018; 14: 837–42.CrossRefGoogle ScholarPubMed
Solomon, A, Kivipelto, M, Molinuevoet, JL, al. European Prevention of Alzheimer’s Dementia Longitudinal Cohort Study (EPAD LCS): study protocol. BMJ Open 2018; 8: e021017.Google Scholar
ten Kate, M, Ingala, S, Schwarz, A, et al. Secondary prevention of Alzheimer’s dementia: neuroimaging contributions. Alzheimers Res Ther 2018; 10: 112.CrossRefGoogle Scholar
Ritchie, K, Ropacki, M, Albala, B, et al. Recommended cognitive outcomes in preclinical Alzheimer’s disease: consensus statement from the European Prevention of Alzheimer’s Dementia project. Alzheimers Dement 2017; 13: 186–95.CrossRefGoogle ScholarPubMed
Mortamais, M, Ash, J, Harrison, J, et al. Detecting cognitive changes in preclinical Alzheimer’s disease: a review of its feasibility. Alzheimers Dement 2017; 13: 468–92.CrossRefGoogle ScholarPubMed
Ritchie, K, Carriere, I, Howett, D, et al. Allocentric and egocentric spatial processing in middle-aged adults at high risk of late-onset Alzheimer’s disease: the PREVENT Dementia Study. J Alzheimers Dis 2018; 65: 885–96.CrossRefGoogle ScholarPubMed
Ritchie, CW, Muniz-Terrera, G, Kivipelto, M, et al. The European Prevention of Alzheimer’s Dementia (EPAD) longitudinal cohort study: baseline data release V500.0. J Prev Alzheimers Dis 2019; 7: 8–13.Google Scholar
Ingala, S, De Boer, C, Masselink, LA, the EPAD consortium. Application of the ATN classification scheme in a population without dementia: findings from the EPAD cohort. Alzheimers Dement 2021;DOI: http://doi.org/10.1002/alz.12292.Google Scholar
Angus, D, Alexander, B, Berry, S, et al. Adaptive platform trials: definition, design, conduct, and reporting considerations. Nat Rev Drug Discov 2019; 18: 797–807.Google Scholar
Frisoni, G, Ritchie, C, Carrera, E, et al. Re-aligning scientific and lay narratives of Alzheimer’s disease. Lancet Neurol 2019; 18: 918–19.Google Scholar
Frisoni, GB, Molinuevo, JL, Altomare, D, et al. Precision prevention of Alzheimer’s and other dementias: anticipating future needs in the control of risk factors and implementation of disease-modifying therapies. Alzheimers Dement 2020; 16: 1457–68.CrossRefGoogle ScholarPubMed
Ritchie, CW, Russ, TC, Banerjee, S, et al. The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease. Alzheimers Res Ther 2017; 9: 85.CrossRefGoogle ScholarPubMed
Jack, CR Jr., Bennett, DA, Blennow, K, et al. NIA–AA Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement 2018; 14: 535–62.CrossRefGoogle Scholar
- 1
- Cited by